These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 8395248)
21. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Meltzer SS; Hasday JD; Cohn J; Bleecker ER Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575 [TBL] [Abstract][Full Text] [Related]
22. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase. Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813 [TBL] [Abstract][Full Text] [Related]
23. Medicinal plants from nepal: evaluation as inhibitors of leukotriene biosynthesis. Kumar S; Ziereis K; Wiegrebe W; Müller K J Ethnopharmacol; 2000 Jun; 70(3):191-5. PubMed ID: 10837982 [TBL] [Abstract][Full Text] [Related]
24. Preclinical and clinical activity of zileuton and A-78773. Bell RL; Lanni C; Malo PE; Brooks DW; Stewart AO; Hansen R; Rubin P; Carter GW Ann N Y Acad Sci; 1993 Nov; 696():205-15. PubMed ID: 8109828 [TBL] [Abstract][Full Text] [Related]
25. Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Bell RL; Harris RR; Bouska JB; Hulkower KI; Moore J; Bhatia P; Malo PE; Kalosa T; Brooks CD; Carter GW Adv Exp Med Biol; 1997; 433():91-4. PubMed ID: 9561111 [No Abstract] [Full Text] [Related]
27. Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors. Satoh Y; Powers C; Toledo LM; Kowalski TJ; Peters PA; Kimble EF J Med Chem; 1995 Jan; 38(1):68-75. PubMed ID: 7837242 [TBL] [Abstract][Full Text] [Related]
28. Lipid mediators in the rat retina: light exposure and trauma elicit leukotriene B4 release in vitro. Reinboth JJ; Gautschi K; Clausen M; Remé CE Curr Eye Res; 1995 Nov; 14(11):1001-8. PubMed ID: 8585927 [TBL] [Abstract][Full Text] [Related]
29. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271 [TBL] [Abstract][Full Text] [Related]
30. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. Kachur JF; Askonas LJ; Villani-Price D; Ghoreishi-Haack N; Won-Kim S; Liang CD; Russell MA; Smith WG J Pharmacol Exp Ther; 2002 Feb; 300(2):583-7. PubMed ID: 11805220 [TBL] [Abstract][Full Text] [Related]
33. WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Carlson R; Kreft A; Hartman D; Tomchek L; Lock Y; Weichman B; Glaser K Prostaglandins Leukot Essent Fatty Acids; 1999 Jan; 60(1):31-41. PubMed ID: 10319915 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of leukotriene B4 biosynthesis by disulfiram and A-64077 during carrageenan-induced pleurisy in the rat. Riendeau D; Guay J; Foster A; Wolfe S; Chan CC Gen Pharmacol; 1991; 22(2):371-4. PubMed ID: 1647348 [TBL] [Abstract][Full Text] [Related]
35. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321 [TBL] [Abstract][Full Text] [Related]
36. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452 [TBL] [Abstract][Full Text] [Related]
37. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase. Kimble E; Kowalski T; White D; Raychauduri A; Pastor G; Chertock H; Lee W; Neale R; Hamdan A; Wasley J Agents Actions; 1991 Sep; 34(1-2):125-8. PubMed ID: 1665286 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of leukotriene biosynthesis in the rat peritoneal cavity. Young PR; Bell RL; Lanni C; Summers JB; Brooks DW; Carter GW Eur J Pharmacol; 1991 Dec; 205(3):259-66. PubMed ID: 1817962 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies. Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466 [TBL] [Abstract][Full Text] [Related]
40. Granulocyte-macrophage colony-stimulating factor increases the synthesis of leukotriene B4 by human neutrophils in response to platelet-activating factor. Enhancement of both arachidonic acid availability and 5-lipoxygenase activation. McColl SR; Krump E; Naccache PH; Poubelle PE; Braquet P; Braquet M; Borgeat P J Immunol; 1991 Feb; 146(4):1204-11. PubMed ID: 1846895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]